SEC Form 4
Roivant Sciences Ltd. Common Shares (ROIV) insider trading
In the 12 months to Oct 26, 2026, 12 ROIV insiders reported open-market sales of $878.5M across 45 filings; no open-market purchases were filed.
Latest filing · Last 12 months · Source: SEC EDGAR · How we count
- Open-market sales
- $878.5M
- 45 filings · 12 insiders
- Open-market purchases
- $0
- 0 filings
- Pre-arranged sales (10b5-1)
- 19 of 45
- $155.5M of $878.5M sold (18%)
Who traded ROIV, and when
- Sale
- Sale, pre-arranged (10b5-1)
ROIV daily close from Oct 27, 2025 to Oct 26, 2026, between $18.41 and $41.81, last $36.02. 45 sale and 0 purchase filings by 12 insiders, marked at their filing dates. Keith S. Manchester, Director: sold $154.5M across 4 filings, first filed Nov 21, 2025, last Jun 30, 2026. Daniel Allen Gold, Director: sold $147.4M across 4 filings, first filed Nov 21, 2025, last Jun 30, 2026. QVT Financial LP, Other: sold $147.4M across 4 filings, first filed Nov 21, 2025, last Jun 30, 2026. Mayukh Sukhatme, President & CIO: sold $109.1M across 6 filings, first filed Dec 19, 2025, last Aug 21, 2026. Vivek Ramaswamy, 10% owner: sold $105.9M across 2 filings, first filed Nov 17, 2025, last Dec 15, 2025. Frank Torti, President and Vant Chair: sold $82.0M across 1 filing, first filed Feb 23, 2026, last Feb 23, 2026. 6 others: sold $132.2M across 24 filings, first filed Nov 7, 2025, last Oct 22, 2026.
Largest mark · tap a row for others
Frank Torti · President and Vant Chair
Sale $82,039,460
3,000,000 shares at $27.35 avg
Filed Feb 23, 2026 · traded Feb 19
Pre-arranged (10b5-1) · close on filing date $27.76
Keith S. Manchester · Director
Director
$154.5M soldDaniel Allen Gold · Director
Director
$147.4M soldQVT Financial LP · Other
Other
$147.4M soldMayukh Sukhatme · President & CIO
President & CIO
$109.1M soldVivek Ramaswamy · 10% owner
10% owner
$105.9M soldFrank Torti · President and Vant Chair
President and Vant Chair
$82.0M sold6 others
Combined, one mark per week
$132.2M soldOpen-market trades
45 filings in the last 12 months| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
|---|---|---|---|---|---|---|
| Keith S. Manchester | Director | $154.5M | — | 4 | — | |
| Daniel Allen Gold | Director | $147.4M | — | 4 | — | |
| QVT Financial LP | Other | $147.4M | — | 4 | — | |
| Mayukh Sukhatme | President & CIO | $109.1M | — | 6 | — | |
| Vivek Ramaswamy | 10% owner | $105.9M | — | 2 | — | |
| Frank Torti | President and Vant Chair | $82.0M | — | 1 | 100% of sales | |
| Eric Venker | President & Immunovant CEO | $70.6M | — | 12 | 100% of sales | |
| Matthew Gline | CEO | $46.2M | — | 2 | — | |
| Richard Pulik | CFO | $9.1M | — | 1 | — | |
| Meghan Fitzgerald | Director | $3.3M | — | 4 | 41% of sales | |
| Epperly Melissa B | Director | $2.6M | — | 4 | 55% of sales | |
| Jennifer Humes | Chief Accounting Officer | $384.1K | — | 1 | — |
| Filed | Insider | Type | Shares | Avg price | Value | Held after | Source |
|---|---|---|---|---|---|---|---|
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $35.11 | $7.0M | 1,413,298 | |
traded | Epperly Melissa B Director | SalePre-arranged (10b5-1) | 17,750 | $36.10 | $640.9K | 15,854 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $36.62 | $7.3M | 1,599,154 | |
traded | Meghan Fitzgerald Director | SalePre-arranged (10b5-1) | 5,112 | $39.74 | $203.2K | 36,108 | |
traded | Epperly Melissa B Director | SalePre-arranged (10b5-1) | 4,938 | $39.74 | $196.2K | 10,500 | |
traded | Meghan Fitzgerald Director | SalePre-arranged (10b5-1) | 20,000 | $39.90 | $798.0K | 42,963 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $35.77 | $7.2M | 1,632,972 | |
traded | Mayukh Sukhatme President & CIO | Sale | 335,174 | $36.88 | $12.4M | 18,630,739 | |
traded | Mayukh Sukhatme President & CIO | Sale | 664,826 | $36.34 | $24.2M | 18,630,739 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $34.95 | $7.0M | 1,613,063 | |
traded | Meghan Fitzgerald Director | SalePre-arranged (10b5-1) | 10,000 | $34.90 | $349.0K | 42,963 | |
traded | Epperly Melissa B Director | SalePre-arranged (10b5-1) | 17,750 | $34.38 | $610.3K | 19,222 | |
traded | QVT Financial LP Other | Sale | 1,438,163 | $34.32 | $49.4M | 13,689,166 | |
traded | Daniel Allen Gold Director | Sale | 1,438,163 | $34.32 | $49.4M | 13,689,166 | |
traded | Keith S. Manchester Director | Sale | 1,638,163 | $34.46 | $56.4M | Multiple accounts | |
traded | Mayukh Sukhatme President & CIO | Sale | 1,000,000 | $34.11 | $34.1M | 18,677,617 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $33.16 | $6.6M | 1,613,063 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $30.27 | $6.1M | 1,613,063 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $29.59 | $5.9M | 1,647,546 | |
traded | Matthew Gline CEO | Sale | 289,774 | $29.16 | $8.4M | 16,736,116 | |
traded | Jennifer Humes Chief Accounting Officer | Sale | 13,538 | $28.37 | $384.1K | 84,191 | |
traded | Meghan Fitzgerald Director | Sale | 70,000 | $27.45 | $1.9M | 42,963 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $28.24 | $5.6M | 1,647,546 | |
traded | Epperly Melissa B Director | Sale | 41,861 | $28.68 | $1.2M | 15,804 | |
traded | Frank Torti President and Vant Chair | SalePre-arranged (10b5-1) | 3,000,000 | $27.35 | $82.0M | 13,736,547 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $26.49 | $5.3M | 1,654,597 | |
traded | QVT Financial LP Other | Sale | 1,225,784 | $26.64 | $32.7M | 15,127,329 | |
traded | Daniel Allen Gold Director | Sale | 1,225,784 | $26.64 | $32.7M | 15,352,329 | |
traded | Keith S. Manchester Director | Sale | 1,225,784 | $26.64 | $32.7M | 15,127,329 | |
traded | Mayukh Sukhatme President & CIO | Sale | 339,441 | $26.47 | $9.0M | 19,148,664 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $21.92 | $4.4M | 1,654,597 | |
traded | Mayukh Sukhatme President & CIO | Sale | 1,330,868 | $21.72 | $28.9M | 20,267,429 | |
traded | Richard Pulik CFO | Sale | 406,731 | $22.43 | $9.1M | 386,144 | |
traded | Mayukh Sukhatme President & CIO | Sale | 26,831 | $23.09 | $619.5K | 18,869,229 | |
traded | QVT Financial LP Other | Sale | 1,694,614 | $23.05 | $39.1M | 16,697,727 | |
traded | Keith S. Manchester Director | Sale | 1,694,614 | $23.05 | $39.1M | 16,542,651 | |
traded | Daniel Allen Gold Director | Sale | 1,694,614 | $23.05 | $39.1M | 16,542,651 | |
traded | Matthew Gline CEO | Sale | 1,740,000 | $21.68 | $37.7M | 18,084,676 | |
traded | Vivek Ramaswamy 10% owner | Sale | 3,103,745 | $21.89 | $67.9M | 34,132,463 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $20.85 | $4.2M | 1,497,908 | |
traded | QVT Financial LP Other | Sale | 1,300,000 | $20.23 | $26.3M | 18,497,727 | |
traded | Daniel Allen Gold Director | Sale | 1,300,000 | $20.23 | $26.3M | 18,222,727 | |
traded | Keith S. Manchester Director | Sale | 1,300,000 | $20.23 | $26.3M | 18,047,727 | |
traded | Vivek Ramaswamy 10% owner | Sale | 1,854,603 | $20.46 | $37.9M | 33,653,756 | |
traded | Eric Venker President & Immunovant CEO | SalePre-arranged (10b5-1) | 200,000 | $20.22 | $4.0M | 1,504,959 |
GET /stocks/filings/vX/form-4?tickers=ROIV&filing_date.gte=2025-10-26&sort=filing_date.desc&limit=500{
"status": "OK",
"results": [
{
"tickers": [
"ROIV"
],
"issuer_cik": "0001635088",
"owner_cik": "0001801917",
"accession_number": "0001635088-26-000116",
"form_type": "4",
"filing_date": "2026-10-22",
"period_of_report": "2026-10-20",
"issuer_name": "Roivant Sciences Ltd.",
"issuer_trading_symbol": "ROIV",
"owner_name": "Venker Eric",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President & Immunovant CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 14144,
"transaction_price_per_share": 35.42,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1399154,
"transaction_value": 500980.48000000004,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F2",
"description": "The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.39 to $35.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026."
}
]
},
{
"tickers": [
"ROIV"
],
"issuer_cik": "0001635088",
"owner_cik": "0001801917",
"accession_number": "0001635088-26-000116",
"form_type": "4",
"filing_date": "2026-10-22",
"period_of_report": "2026-10-20",
"issuer_name": "Roivant Sciences Ltd.",
"issuer_trading_symbol": "ROIV",
"owner_name": "Venker Eric",
"is_director": false,
"is_officer": true,
"is_ten_percent_owner": false,
"is_other": false,
"officer_title": "President & Immunovant CEO",
"security_type": "non_derivative",
"record_type": "transaction",
"security_title": "Common Shares",
"transaction_timeliness": "O",
"aff_10b5_one": true,
"transaction_date": "2026-10-20",
"transaction_code": "S",
"equity_swap_involved": false,
"transaction_shares": 185856,
"transaction_price_per_share": 35.09,
"transaction_acquired_disposed": "D",
"shares_owned_following_transaction": 1413298,
"transaction_value": 6521687.040000001,
"not_subject_to_section_16": false,
"direct_or_indirect": "D",
"footnotes": [
{
"id": "F1",
"description": "The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.38 to $35.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on June 30, 2026."
}
]
}
]
}
// trimmed to 2 resultsThe response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.
Other insider activity (not market trades) · 113 records
- Option exercises43 records
- Tax withholding38 records
- Tax withholding (sold to cover)2 records
- Grants and awards18 records
- Gifts1 record
- Other11 records
Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.
How to read this page
- Open-market purchase or sale
- A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- Pre-arranged (10b5-1)
- The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- Filing date
- Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.
Frequently asked questions
Has Roivant Sciences Ltd. Common Shares' CEO sold stock?
Yes. Eric Venker (CEO) sold 2,400,000 shares ($70.6M) between Nov 2025 and Oct 2026, all under a pre-arranged 10b5-1 plan. Matthew Gline (CEO) sold 2,029,774 shares ($46.2M) between Dec 2025 and Apr 2026.
How current is ROIV’s insider data?
These are ROIV Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.
What counts as an open-market buy or sell?
Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.
Build with AI
Track ROIV insider trades with your agent
This page joins two Massive endpoints: Form 4 filings and daily prices. Ask an agent to watch for new filings:
Using the Massive API (massive.com/docs/llms.txt), check Form 4 filings for ROIV every day with transaction_code=P and tell me when an insider files an open-market purchase, with their role, shares, price and the filing link.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.